Home › NDC Lookup › Ingredients › Lidocaine › 39328-0024-55
Lidocaine 40 mg/g Cream — NDC 39328-0024-55 package photo

Lidocaine 40 mg/g Cream

by Patrin Pharma Inc. · 5 TUBE in 1 CARTON (39328-024-55) / 5 g in 1 TUBE
NDC 39328-0024-55
🏷️ FDA NDC (as labeled) 39328-024-55 billing pads the product segment with a zero
This package
Contains5 g in 1 tube Medicaid pays$0.6645 / unit · 12 mo Per package$16.61 / 25 g · Medicaid Pack sizes4 compare ↓
Also comes in: 15 g 39328-0024-15 30 g 39328-0024-30 5 tubes 39328-0024-56
OTC On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Lidocaine (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class III · Apr 20, 2023 — Labeling: Typographical error on the upper left-hand side of the box and individual patch label that has the incorrect dosage form stating, each tablet contains instead of each adhesive patch contains. (Bryant Ranch Prepack, Inc.) · FDA recall D-0556-2023
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

🆔 Identity & classification

FDA NDC (as labeled) 39328-024-55
Product NDC 39328-024
11-digit billing NDC 39328002455
NCPDP billing unit GM — per gram (weight)
RxCUI 1421893
UNII 98PI200987
Application # M017
SPL Set ID 91eedf9d-53b8-49d5-af59-25019606a0b2
Established class (EPC) Amide Local Anesthetic; Antiarrhythmic
Physiologic effect Local Anesthesia
Chemical class Amides
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2018-11-01
Route TOPICAL
Dosage form CREAM
Substance LIDOCAINE
GPI-14 90850060003720
GPI class Lidocaine
GCN Seq No 040262
GCN 95405
HICL code 010705
Ingredient (HICL) Lidocaine
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5H
Therapeutic class — specific (HIC3) Topical Local Anesthetics
AHFS code 72:00.00.00
AHFS class Local Anesthetics
FDB label name LIDOCAINE 4% CREAM
FDB brand name Lidocaine
Legend status O — Over-the-counter (OTC) drug or device
Why two NDCs? The FDA registers this code as 39328-024-55 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 39328-0024-55. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Antiarrhythmic class.

Pharmacologic class Antiarrhythmic, Amide Local Anesthetic
Drug family (ATC) Antiarrhythmics, class Ib, Local anesthetics, Anesthetics for topical use
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerPatrin Pharma Inc.
FDA applicationM017 (OTC MONOGRAPH DRUG)
Labeler code39328
First marketedNov 2018
Product typeHuman Otc Drug
Portfolio3 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name LIDOCAINE 4% CREAM Ingredient Lidocaine
📗 Our plain-language guide HelloPharmacist
  • It's best to avoid using two lidocaine products at the same time unless your doctor says it's okay. When you use multiple products containing a local anesthetic, the total amount a...
  • Can I use a lidocaine patch and a lidocaine cream at the same time?
  • No — please don't do this. Heat significantly increases how much lidocaine is absorbed through your skin, which can push drug levels in your blood higher than they should be. Stick...
  • Can I put a heating pad on the area where I applied a lidocaine patch?
📖 Read our full Lidocaine guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color White
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 9E8X80D2L0
    A synthetic form of vitamin E used as an antioxidant and preservative in medications. It helps prevent the active ingredients from degrading when exposed to oxygen or light.
  • UNII LKG8494WBH
    Benzyl alcohol is a clear liquid used as a preservative and solvent in medicines. It helps prevent bacterial and fungal growth and dissolves other ingredients to create uniform liquid formulations.
  • UNII 4Q93RCW27E
    A synthetic polymer made from acrylic acid that's crosslinked for stability. It acts as a thickener and gelling agent in creams and gels, helping the medicine spread evenly and maintain its texture.
  • UNII H1109Z9J4N
    A natural emulsifier derived from soybean oil. It helps mix oil and water-based ingredients together, ensuring even distribution of active ingredients throughout the medicine.
  • UNII 6OZP39ZG8H
    Polysorbate 80 is a synthetic emulsifier derived from sorbitol and oleic acid. It helps mix oil and water-based ingredients together in medications and improves how the product disperses in the body.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII 9O3K93S3TK
    Trolamine is an alkaline compound used as a pH buffer and emulsifier in medicines. It helps neutralize acids, stabilize formulations, and enable mixing of oil and water-based ingredients.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

8 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statesBenzyl Alcohol, Carbomer, Hydrogenated Lecithin, Polysorbate 80, Propylene Glycol, Purified Water, Trolamine and Vitamin E Acetate.

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo $0.6645 $16.61 / 25 g
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Rugby Lidocaine 4 g/100g 00536-1357-95 Rugby 1 tube $0.410 — Availability likely —
Lidocaine 4% Topical Anesthetic Cream 4 g/100g 83720-0523-01 Oncor 1 tube $0.482 — Availability likely —
4 Lidocaine Topical Anesthetic 40 mg/g 00536-1267-20 RUGBY 15 g $0.597 — Availability likely —
Numbing Pain Relief 4 g/100g 00363-6261-07 Walgreen 1 applicator — — FDA listed —
Lmx4 40 mg/g 00496-0882-05 Ferndale 5 g — — FDA listed —
Lidocaine 40 mg/g 10135-0672-96 Marlex 1 tube — — FDA listed —
Anecream 4 g/100g 24357-0701-06 Focus 5 tubes — — FDA listed —
Lidocaine 40 mg/gthis 39328-0024-55 Patrin 5 tubes — — FDA listed —
Meijer Analgesic Lidocaine Topical Analgesic 40 mg/g 41250-0518-01 Meijer 1 bottle — — FDA listed —
Lidocaine 4 g/100g 42291-0399-30 AvKARE 1 tube — — FDA listed —
Pain free IV 4 g/100mL 54723-0008-01 Sambria 4 ml — — FDA listed —
Painless Tattoo 2 4 g/100mL 54723-0016-01 Sambria 4 ml — — FDA listed —
NeuroMed Topical Anesthetic 7 40 mg/g 54723-0300-04 Sambria 4 g — — FDA listed —
Family Wellness Pain Relief with Lidocaine 40 mg/g 55319-0822-50 FAMILY 1 tube — — FDA listed —
Lidocaine 40 mg/g 58980-0824-05 Stratus 1 tube — — FDA listed —
Burn Relief Professional Bio-Kool 4 g/100g 61566-0201-04 Kool-Down 113 g — — FDA listed —
Desert Harvest RELEVEUM 40 mg/mL 69145-0201-04 Desert 118 ml — — FDA listed —
Lidocaine Anesthetic Cream 4 g/100g 69375-0005-30 Nationwide 1 tube — — FDA listed —
Tylenol Precise Warming Pain Relieving 40 mg/g 69968-0794-04 Kenvue 1 tube — — FDA listed —
Tylenol Precise Pain Relieving 40 mg/g 69968-0795-04 Kenvue 1 tube — — FDA listed —
Blue-Emu Lidocaine Pain Relief Cream 40 mg 69993-0350-03 Kingsway 1 tube — — FDA listed —
Lidocaine Cream, 4% 4 g/100g 71085-0075-19 IPG 119 g — — FDA listed —
Deeveeant Numb 40 mg/g 71383-0014-02 Valekista 1 tube — — FDA listed —
MediNumb 40 mg/g 71383-0024-02 Valekista 1 tube — — FDA listed —
Asper Flex 4 g/100g 71399-0049-01 Akron 15 g — — FDA listed —
Lidocaine 4% 4 g/100g 71800-0026-06 Innovida 58.5 g — — FDA listed —
Lidozall 4 g/100g 72835-0004-20 V2 20 packets — — FDA listed —
Lidocaine 4% Topical Anesthetic Cream 4.27 g/100g 73715-0001-01 Mohnark 30 g — — Discontinued —
Meijer Pain Relief Cream 4 g/100g 79481-0048-02 Meijer 76.5 g — — FDA listed —
Lidocaine 40 mg/g 80425-0351-01 Advanced 1 tube — — FDA listed —
Lidocaine 4% Cream 40 mg/g 82461-0419-30 Medcore 1 tube — — FDA listed —
AUVON Pain Relief Cream 4 g/100g 83391-0009-01 SHENZHEN 57 g — — FDA listed —
RelaxInk LIDOCAINE 4 g/100g 83714-0004-01 Hambli 1 tube — — FDA listed —
ELAIMEI Numbing Cream 4 g/100mL 83804-0005-01 Shenzhen 1 bottle — — FDA listed —
Tktalker Numbing 4 g/100g 83804-0113-01 Shenzhen 50 g — — FDA listed —
Dcsily Numbing Cream 4 g/100g 83818-0034-01 Shenzhen 50 g — — FDA listed —
4% TATTOO Numb Cream 100 mg/g 84019-0030-01 Shengnan 30 g — — FDA listed —
Signature Pain Relief Cream 40 mg/g 84019-0044-01 Shengnan 30 g — — FDA listed —
Nekvnro LIDOCAINE 4% Tattoo numbing cream set 4 g/100g 84844-0018-01 Guoyu 2 tubes — — Discontinued —
VBBV Tattoo Numbing 40 mg/mL 84867-0014-01 Jiashen 60 ml — — FDA listed —
Black Cobra Tattoo Numbing Cream 4% Lidocaine .04 g/g 84938-0002-01 Foshan 20 g — — FDA listed —
Jakwork Numbing Cream 4 g/100g 85150-0007-01 Guangzhou 50 g — — FDA listed —
Healmusz Numbing 4 g/100g 85248-0032-01 Jiangxi 50 g — — FDA listed —
Nieapf NUMBING 4 g/100g 85248-0046-01 Jiangxi 65 g — — FDA listed —
Subleef NUMBING 4 g/100g 85248-0052-01 Jiangxi 30 g — — FDA listed —
Sylvirene Numbing 4 g/100g 85248-0070-01 Jiangxi 50 g — — FDA listed —
ANIXIKE Numbing 4 g/100g 85248-0088-01 Jiangxi 30 g — — FDA listed —
Dermfree Numbing 4 g/100g 85248-0121-01 Jiangxi 50 g — — FDA listed —
ANIXIKE Numbing 4 g/100g 85248-0166-01 Jiangxi 30 g — — FDA listed —
YYSDMVY NUMBING Cream 4 g/100g 85248-0209-01 Jiangxi 60 g — — FDA listed —
Tattoo numbing cream 4 g/100g 85284-0001-01 BLOOMWELL 50 g — — FDA listed —
Topical Cream 4 g/100g 85284-0002-01 BLOOMWELL 50 g — — Discontinued —
Numbing Cream 4 g/100g 85284-0003-01 BLOOMWELL 50 g — — Discontinued —
numbing cream MAXIMUM STRENGTH 4 g/100g 85284-0006-01 BLOOMWELL 50 g — — Discontinued —
Veiurkiu External Analgesic Cream 4 g/100g 85284-0011-01 BLOOMWELL 50 g — — FDA listed —
Numbing Cream 40 mg/g 85569-0001-01 100 50 g — — FDA listed —
Numbing Cream 4 mg/100mL 85569-0002-01 100 50 ml — — FDA listed —
SCHOELIF Numbing Cream 4 g/100g 85817-0001-01 Guangzhou 50 g — — FDA listed —
Aouiv 4% Lidocaine Numbing Cream 4 g/100g 85817-0003-01 Guangzhou 60 g — — FDA listed —
Numbing Creams 4 g/100g 85881-0001-01 Yongchun 50 g — — FDA listed —
Black Cobra 4% Lidocaine Numbing Cream 40 mg/g 85924-0001-02 BLACKCOBRASUPPLY, 1 tube — — Discontinued —
Swiftalyn Numbing Cream 4 g/100g 87013-0002-01 GENUINE 50 g — — FDA listed —
Morovan 4 g/100g 87800-2624-01 HONG 1 can — — FDA listed —
Greencaine Blast 40 mg/g 69747-0040-01 ALMA 113 g — — FDA listed —
Bed Bug Instant Bite Relief 40 mg/g 70466-0001-01 P.F. 1 tube — — FDA listed —
BENGAY Tropical Jasmine 40 mg/g 69968-0614-03 Kenvue 1 tube — — FDA listed —
Hush Anesthetic 40 mg/g 49947-0002-02 HUSH 56.7 g — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2018
On the market since
Nov 2018
📍
2026
Currently FDA-listed
8 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 39328-0024-55, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
88
Units reimbursed last 4 qtrs
2.7K
Gross reimbursed last 4 qtrs
$1.8K
Avg / prescription
$20.16
Avg / unit
$0.6645
Latest quarter Q4 2025
11Rx
Fee-for-service vs managed care ⓘ
100% MCO
Fee-for-service · 0 Rx Managed care · 88 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: no data reported NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: 1,420 units · 44.5 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 1,250 units · 10.6 per 100k residents OH Pennsylvania: no data reported PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
10.644.5
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Nevada 44.5 /100k
2 Ohio 10.6 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tube39328-0024-30 19,092 Rx · $583,407
1 tube39328-0024-15 7,274 Rx · $212,763
5 tubes this page39328-0024-55 88 Rx · $1,774
5 tubes39328-0024-56 No Medicaid data
Drug total (last 4 qtrs): 26,454 Rx · 1,151,615 units · $797,944 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Lidocaine — the program that covers self-administered drugs. 17 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Lidocaine. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$53.12M
Claims incl. refills
593.7K
Beneficiaries
367.9K
Spend / beneficiary
$144.39
Spend / claim
$89.46
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Lidocaine — the ingredient across all brands.

Top reported reactions

Pain5,190
Nausea4,961
Fatigue4,867
Headache4,439
Product Quality Issue3,920
Dyspnoea3,658
Product Adhesion Issue3,514

Age at onset

Neonate191
Infant95
Child490
Adolescent342
Adult7,266
Elderly4,622

Reporter sex

96,036 reports
Male · 33%
Female · 66%
Unknown · 0%

Serious outcomes

Hospitalization26,850
Death7,429
Life-threatening6,105
Disabling2,002
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 7,424 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
39328-0024-15 1 TUBE in 1 CARTON (39328-024-15) / 15 g in 1 TUBE $0.5969 / g $8.95 2018-11-01 Active
39328-0024-30 1 TUBE in 1 CARTON (39328-024-30) / 30 g in 1 TUBE $0.4825 / g $14.47 2018-11-01 Active
39328-0024-55 You're viewing this 5 TUBE in 1 CARTON (39328-024-55) / 5 g in 1 TUBE — — 2018-11-01 Active
39328-0024-56 5 TUBE in 1 CARTON (39328-024-56) / 5 g in 1 TUBE — — 2018-11-01 Active

Pack size FAQ

What quantity is in NDC 39328-0024-55?
NDC 39328-0024-55 is listed by the FDA — 5 tube in 1 carton / 5 g in 1 tube.
What NDC number is used to bill for this package of Lidocaine 40 mg/g Cream?
Bill NDC 39328-0024-55 — the 11-digit billing format is 39328002455. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

🧭 About this NDC listing & data coverage

Over-the-counter (OTC) product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Otc Monograph Drug". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 39328-024-55, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 39328-0024-55, written without dashes as 39328002455. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 39328-0024-55, the first segment (39328) is the labeler code FDA assigned to Patrin Pharma Inc.; the middle segment (0024) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (55) identifies this exact package size and type. Together they name one specific package of one specific product.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Patrin Pharma Inc.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 3 other package presentations of this same product, including 1 tube (39328-0024-15), 1 tube (39328-0024-30), 5 tubes (39328-0024-56). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Patrin Pharma Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as an over-the-counter product, so it does not require a prescription. Follow the package directions, and ask your pharmacist if you are unsure whether it is right for you.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.

📄 FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 📦 Storage and Handling 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose
🎯 Indications and Usage 20 words ▾

Uses temporarily relieves pain and itching due to minor cuts minor scrapes minor burns sunburn minor skin irritation insect bites

⏱️ Dosage and Administration 31 words ▾

Directions Adult and children 2 years and older: Apply externally to the affected area up to 3 to 4 times a day. Children under 2 years of age: Consult a doctor.

⚠️ Warnings 79 words ▾

Warnings For external use only. Do not use in or near the eyes in large quantities, particularly over raw or blistered areas Stop use and ask a doctor if allergic reaction occurs condition worsens or does not improve within 7 days symptoms clear up and return within a few days redness, irritation, swelling, pain or other symptoms begin or increase Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

📦 Storage and Handling 23 words ▾

Other Information May be applied under occlusive dressing. Store at room temperature, 20-25°C (68-77°F) Excursions permitted 15-30°C (59-86°F) [see USP Controlled Room Temperature].

🧪 Active Ingredient 5 words ▾

Active Ingredient Lidocaine 4% w/w

🧪 Inactive Ingredients 18 words ▾

Inactive ingredients Benzyl Alcohol, Carbomer, Hydrogenated Lecithin, Polysorbate 80, Propylene Glycol, Purified Water, Trolamine and Vitamin E Acetate.

🎯 Purpose 3 words ▾

Purpose Topical anesthetic

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 39328-0020-08 · Patrin 39328-0025-15 · Patrin →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.